Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery.
Thousand Oaks, CA
Joined September 2017
- Tweets57
- Following333
- Followers222
- Likes276
Pinned Tweet
Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain.
Full press release: tinyurl.com/qk4vtzm
Dyve’s science has demonstrated the power to deliver up to 40% of the applied dose into the blood, which exceeds what is seen by many pills. #biotech
Thank you to @MassDevice for highlighting Dyve's press release announcing first patient enrollment in Phase 2 TARGETS Study for Acute Gout: bit.ly/2PcQfiu
#gout #biotech #clinicaltrials
Thank you @Machiz and @Nasdaq for featuring Dyve in their #NasdaqSpotlight series in New York City last week! You can view the full interview with CEO Ryan Beal on Dyve's website: bit.ly/38LLx2M
#biotech #healthcare
We had an exciting week in New York! Thank you to @IAmBiotech for hosting #BIOCEO20 as well as @Nasdaq for highlighting Dyve on #NasdaqSpotlight! #biotech
Thanks to @byndergroup for their continued partnership and the amazing work they've put into developing our website! dyvebio.com
This Post is from an account that no longer exists. Learn more
Dyve Biosciences retweeted
BIO is helping leaders fulfill that commitment by providing resources to help build a more inclusive and diverse workforce. Learn more at buff.ly/2S3JkIT #rightmixmatters
Dyve is thrilled to welcome longtime Pfizer Executive Chuck Harbert, Ph.D. to the company in the role of Chief Scientific Officer.
Full press release: tinyurl.com/yexnmx99
Learn more about Dyve: dyvebio.com
Gout flares are characterized by the formation of sodium urate crystals in the joint space, causing intense pain typically lasting 48-96 hours.
Dyve Biosciences retweeted
.@DyveBio wins FDA nod for Phase 2 transdermal drug delivery trial bit.ly/2PpPnYc
DYV-700 was recently approved for phase 2 trial for treatment of acute gout pain. Here's why we're excited.
CEO Ryan Beal, MD chatted with @ModAesthetics about the latest research on Dyve's technology.
Check out the full article: bit.ly/2OugRKK
Dyve Biosciences retweeted
When should lasers be used to treat #melasma? Mildred López Piñeiro, M.D. provides her insight in our new column on energy devices. buff.ly/2QqsUeJ
Dyve's SAB member Smitha Reddy, MD with CEO Ryan Beal, MD before Dr. Reddy's poster presentation at #ACR19 in Atlanta.
For the complete poster, visit our publications page on our website:
dyvebio.com/newsroom/publica…
Great energy this morning at #BIO19. Dyve CEO Ryan Beal MD speaking to "Reimagining Transdermal Drug Delivery".
Dyve CEO Ryan Beal, M.D. will be presenting at Bio Investor Forum next week in San Fran.
Topic is "Reimagining transdermal drug delivery: subcutaneous injections in a topical cream"
Tuesday, October 22nd 9:00 AM
The Westin St. Francis, Elizabethan B
#BIO19 #BioInvestor
Dyve Biosciences will be in Boston next week for #PODD2019. CEO Ryan Beal, MD will be presenting on the power and potential of Dyve’s transdermal drug delivery technology on October 7th at 5:00pm (Track 2A).
Learn more: dyvebio.com
Over half of postpartum women suffer from melasma. Our transdermal delivery system delivers significant and fast reduction in pigmentation with results that meet or exceed current treatment options.
Learn more: dyvebio.com
#biotech #aesthetic #bioinvestor #investor